Show simple item record

dc.contributor.authorAntoun Reyad, Ayman
dc.contributor.authorCooper, Hannah
dc.contributor.authorMishriky, Raafat
dc.date.accessioned2020-02-27T11:35:41Z
dc.date.available2020-02-27T11:35:41Z
dc.date.issued2020-04-15
dc.identifier.citationAntoun Reyad, A., Cooper, H. and Mishriky, R. (2020) Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials, Psychiatria Danubina, 32(1), pp. 36-45 https://doi.org/10.24869/psyd.2020.36en
dc.identifier.issn0353-5053en
dc.identifier.doi10.24869/psyd.2020.36
dc.identifier.urihttp://hdl.handle.net/2436/623096
dc.description.abstractBackground: Cariprazine is a new atypical antipsychotic drug approved for the treatment of schizophrenia and bipolar disorders. Methods: we searched the published randomized controlled-trials (RCT) to review cariprazine efficacy and tolerability using the databases (PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials) for cariprazine role in managing the following psychiatric conditions (schizophrenia, bipolar mania, bipolar depression and major depressive disorder). A meta-analysis was conducted using the identified 13 clinical trials to assess efficacy using with the outcomes: positive and negative syndrome scale (PANSS), clinical global impressions – severity of Illness (CGI-S), young mania rating scales (YMRS), Montgomery Asberg depression rating scale (MADRS) and Hamilton rating scale for depression (HAM-D). The risk of discontinuation due to adverse effects and common side effects were examined. Results: The mean difference in change from baseline for PANSS was -6.23 [95% Confidence Interval (CI) -7.18, -5.28] favoring cariprazine treatment (p<0.00001). Similarly, mean difference for CGI-S was -0.36 [95% CI -0.41, -0.30], YMRS -5.64 [95% CI -6.86, -4.43], MADRS -1.43 [95% CI -1.88, -0.99] and HAM-D -1.52 [95% CI -2.28, -0.76]. The risk ratio (RR) of discontinuing due to adverse events was 1.18 [95% CI 1.01, 1.38] meaning risk increased by 18% in cariprazine group with RR for EPS related side effects 2.82 [95% CI 2.47, 3.22] reflecting an increased risk of experiencing EPS related side effects by 182%. Cariprazine was also associated with an increased incidence of side effects such as akathisia, nausea and insomnia. Conclusion: Cariprazine demonstrates significant improvements in symptom intensity control in patients suffering from psychiatric conditions including schizophrenia, bipolar disorders and depression and is considered well-tolerated with similar rates of trials discontinuation; however, cariprazine was associated with a higher risk of EPS side effects. These findings will guide psychiatrists and pharmacists in their clinical role for supporting psychiatric patients care.en
dc.formatapplication/pdfen
dc.language.isoenen
dc.publisherMedicinska naklada Zagreben
dc.relation.urlhttp://www.psychiatria-danubina.com/en
dc.subjectcariprazineen
dc.subjectschizophreniaen
dc.subjectpsychiatric disordersen
dc.subjectMajor Depressive Disorderen
dc.subjectbipolar disordersen
dc.titleEfficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trialsen
dc.typeJournal articleen
dc.identifier.journalPsychiatria Danubinaen
dc.date.updated2020-02-25T11:29:27Z
dc.date.accepted2020-02-15
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW27022020AARen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2021-04-15en
dc.source.volume32
dc.source.issue1
dc.source.beginpage36
dc.source.endpage45
refterms.dateFCD2020-02-27T11:34:13Z
refterms.versionFCDAM


Files in this item

Thumbnail
Name:
Antoun_Reyad_et_al_Efficacy_an ...
Size:
220.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/